JP2016504351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016504351A5 JP2016504351A5 JP2015550315A JP2015550315A JP2016504351A5 JP 2016504351 A5 JP2016504351 A5 JP 2016504351A5 JP 2015550315 A JP2015550315 A JP 2015550315A JP 2015550315 A JP2015550315 A JP 2015550315A JP 2016504351 A5 JP2016504351 A5 JP 2016504351A5
- Authority
- JP
- Japan
- Prior art keywords
- diastereomer
- enantiomer
- isomer
- compound according
- racemic mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261746980P | 2012-12-28 | 2012-12-28 | |
| US61/746,980 | 2012-12-28 | ||
| PCT/KR2013/012204 WO2014104757A1 (ko) | 2012-12-28 | 2013-12-26 | Btk 키나아제 억제제로서의 2,3-디하이드로-이소인돌-1-온 유도체 및 이를 함유하는 약학적 조성물 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076877A Division JP6596537B2 (ja) | 2012-12-28 | 2018-04-12 | Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016504351A JP2016504351A (ja) | 2016-02-12 |
| JP2016504351A5 true JP2016504351A5 (enExample) | 2017-02-16 |
| JP6325573B2 JP6325573B2 (ja) | 2018-05-16 |
Family
ID=51021712
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015550315A Active JP6325573B2 (ja) | 2012-12-28 | 2013-12-26 | Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物 |
| JP2018076877A Active JP6596537B2 (ja) | 2012-12-28 | 2018-04-12 | Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018076877A Active JP6596537B2 (ja) | 2012-12-28 | 2018-04-12 | Ｂｔｋキナーゼ抑制剤としての２，３−ジヒドロ−イソインドール−１−オン誘導体及びこれを含む薬学的組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9758508B2 (enExample) |
| EP (2) | EP3428161B1 (enExample) |
| JP (2) | JP6325573B2 (enExample) |
| KR (1) | KR102009163B1 (enExample) |
| CN (1) | CN104995184B (enExample) |
| AU (3) | AU2013371146C1 (enExample) |
| BR (1) | BR112015015477B1 (enExample) |
| CA (1) | CA2896711C (enExample) |
| DK (1) | DK2940014T3 (enExample) |
| ES (2) | ES2929906T3 (enExample) |
| MX (2) | MX386542B (enExample) |
| PL (1) | PL2940014T3 (enExample) |
| PT (1) | PT2940014T (enExample) |
| RU (2) | RU2671847C2 (enExample) |
| WO (1) | WO2014104757A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102971322B (zh) | 2010-05-20 | 2016-02-17 | 阵列生物制药公司 | 作为trk激酶抑制剂的大环化合物 |
| PL2940014T3 (pl) * | 2012-12-28 | 2019-03-29 | Crystalgenomics, Inc. | Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna |
| CN108349969B (zh) | 2015-07-16 | 2022-05-10 | 阵列生物制药公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| ES2948194T3 (es) | 2017-01-18 | 2023-09-01 | Array Biopharma Inc | Compuestos de pirazolo[1,5-a]pirazina sustituida como inhibidores de la cinasa RET |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| CA3054196A1 (en) * | 2017-02-21 | 2018-08-30 | Aptose Biosciences Inc. | Methods for treating patients with hematologic malignancies |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| CN111630054B (zh) | 2018-01-18 | 2023-05-09 | 奥瑞生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物 |
| CN111971286B (zh) | 2018-01-18 | 2023-04-14 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡咯并[2,3-d]嘧啶化合物 |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| WO2020055672A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CA3133376A1 (en) * | 2018-11-30 | 2020-06-04 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| EP4274567A1 (en) * | 2021-01-05 | 2023-11-15 | Sumitomo Pharma Oncology, Inc. | Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor |
| US11926625B2 (en) * | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| JP2024513011A (ja) | 2021-03-29 | 2024-03-21 | ニンバス サターン， インコーポレイテッド | Ｈｐｋ１アンタゴニスト及びその使用 |
| WO2024245578A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor |
| WO2024245577A1 (en) | 2023-06-02 | 2024-12-05 | Netherlands Translational Research Center Holding B.V. | Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2246012T3 (es) * | 2001-04-12 | 2006-02-01 | F. Hoffmann-La Roche Ag | Derivados de dihidro benzo(b) (1,4)diacepin-2-ona como antagonistas de mglur2 ii. |
| CA2527814A1 (en) * | 2003-06-02 | 2004-12-16 | Abbott Laboratories | Isoindolin-1-one compounds as kinase inhibitors |
| PE20061119A1 (es) * | 2005-01-19 | 2006-11-27 | Aventis Pharma Sa | PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie |
| AU2006237920A1 (en) * | 2005-04-19 | 2006-10-26 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
| US20070161648A1 (en) * | 2005-10-14 | 2007-07-12 | Hughes Terry V | Substituted dihydro-isoindolones useful in treating kinase disorders |
| CN101405001A (zh) * | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| EP2108642A1 (en) * | 2006-10-17 | 2009-10-14 | Kyowa Hakko Kirin Co., Ltd. | Jak inhibitor |
| EP2426109B1 (en) * | 2007-10-23 | 2013-12-18 | F. Hoffmann-La Roche AG | Novel kinase inhibitors |
| WO2012014017A1 (en) | 2010-07-30 | 2012-02-02 | Poly Medicure Limited | Catheter introducer |
| WO2012047017A2 (ko) * | 2010-10-05 | 2012-04-12 | 크리스탈지노믹스(주) | 2,3-디히드로-이소인돌-1-온 유도체 및 이를 포함하는 조성물 |
| PL2940014T3 (pl) | 2012-12-28 | 2019-03-29 | Crystalgenomics, Inc. | Pochodne 2,3-dihydro-isoindole-1-on jako supresant kinazy btk i mieszanka farmaceutyczna |
| US10463658B2 (en) | 2013-10-25 | 2019-11-05 | Videra Pharmaceuticals, Llc | Method of inhibiting FLT3 kinase |
-
2013
- 2013-12-26 PL PL13867650T patent/PL2940014T3/pl unknown
- 2013-12-26 US US14/655,954 patent/US9758508B2/en active Active
- 2013-12-26 CN CN201380068623.6A patent/CN104995184B/zh active Active
- 2013-12-26 ES ES18190153T patent/ES2929906T3/es active Active
- 2013-12-26 RU RU2015124381A patent/RU2671847C2/ru active
- 2013-12-26 BR BR112015015477-8A patent/BR112015015477B1/pt active IP Right Grant
- 2013-12-26 RU RU2018138028A patent/RU2018138028A/ru unknown
- 2013-12-26 CA CA2896711A patent/CA2896711C/en active Active
- 2013-12-26 DK DK13867650.7T patent/DK2940014T3/en active
- 2013-12-26 PT PT13867650T patent/PT2940014T/pt unknown
- 2013-12-26 MX MX2015008396A patent/MX386542B/es unknown
- 2013-12-26 JP JP2015550315A patent/JP6325573B2/ja active Active
- 2013-12-26 EP EP18190153.9A patent/EP3428161B1/en active Active
- 2013-12-26 EP EP13867650.7A patent/EP2940014B1/en active Active
- 2013-12-26 ES ES13867650T patent/ES2696700T3/es active Active
- 2013-12-26 KR KR1020157018342A patent/KR102009163B1/ko active Active
- 2013-12-26 MX MX2021011563A patent/MX2021011563A/es unknown
- 2013-12-26 WO PCT/KR2013/012204 patent/WO2014104757A1/ko not_active Ceased
- 2013-12-26 AU AU2013371146A patent/AU2013371146C1/en active Active
-
2017
- 2017-08-30 US US15/691,432 patent/US10604508B2/en active Active
-
2018
- 2018-04-12 JP JP2018076877A patent/JP6596537B2/ja active Active
- 2018-08-10 AU AU2018214134A patent/AU2018214134B2/en active Active
-
2020
- 2020-02-14 US US16/791,753 patent/US11230539B2/en active Active
- 2020-02-27 AU AU2020201431A patent/AU2020201431B2/en active Active
-
2022
- 2022-07-22 US US17/871,458 patent/US20220380346A1/en not_active Abandoned